SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 12.16% to Rs. 21443.84 millions for the quarter ended June 2023 as compared to Rs. 19119.30 millions during the corresponding quarter last year.The Company to register a -44.85%  fall in the net profit for the quarter ended June 2023.Operating profit for the quarter ended June 2023 decreased to 5343.57 millions as compared to 7803.42 millions of corresponding quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 21443.84 19119.30 12.16 21443.84 19119.30 12.16 82206.62 81415.81 0.97
Other Income 493.61 3465.18 -85.76 493.61 3465.18 -85.76 9859.39 6146.28 60.41
PBIDT 5343.57 7803.42 -31.52 5343.57 7803.42 -31.52 24587.06 23028.49 6.77
Interest 619.34 397.63 55.76 619.34 397.63 55.76 2068.16 2360.41 -12.38
PBDT 4407.94 7405.79 -40.48 4407.94 7405.79 -40.48 17560.22 24971.41 -29.68
Depreciation 487.52 450.33 8.26 487.52 450.33 8.26 1841.48 1596.95 15.31
PBT 3920.42 6955.46 -43.64 3920.42 6955.46 -43.64 15718.74 23374.46 -32.75
TAX 1203.86 2029.65 -40.69 1203.86 2029.65 -40.69 3631.05 3396.57 6.90
Deferred Tax 818.21 926.08 -11.65 818.21 926.08 -11.65 -238.26 -714.21 -66.64
PAT 2716.56 4925.81 -44.85 2716.56 4925.81 -44.85 12087.69 19977.89 -39.49
Equity 282.17 282.17 0.00 282.17 282.17 0.00 282.17 282.17 0.00
PBIDTM(%) 24.92 40.81 -38.95 24.92 40.81 -38.95 29.91 28.29 5.74

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×